Amendments to the Claims

Claim 1 (currently amended): A compound ~~which is represented by~~ comprising formula (I) ~~below~~



(I)

wherein

R_1 is CH_3 or CH_2CH_3;

R_2 is a *para* and/or *meta* substituted phenyl group;

R_3 is H, CH_3 or CH_2CH_3; and

R_4 is a linear or cyclic aliphatic group, ~~which is optionally substituted,~~

or, wherein

R_1 and R_2 are as stated above while R_3 and R_4 are parts of a 4- to 6-membered cyclic entity, ~~which is optionally substituted,~~

and which compound has affinity for human IgG of κ-type.

Claim 2 (currently amended): ~~A compound according to~~ The compound of claim 1, which is an affinity ligand with affinity for the constant region of a Fab fragment of human IgG of κ-type.

Claim 3 (currently amended): ~~A compound according to~~ The compound of claim 1 ~~or 2~~, wherein R_1 is CH_3.

Claim 4 (currently amended): ~~A~~ The compound of claim 1 ~~according to any one of the preceding claims~~, wherein R_2 ~~comprises~~ is a substituted phenyl group ~~and the~~ having substituents ~~are~~ selected from the group ~~that consists~~ consisting of F, Cl, Br, I and O.

Claim 5 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 1, wherein the phenyl group of R_2 is substituted in the *para* position with a group ~~defined as~~ $-O-R_5$, wherein R_5 is either CH_3 or CH_2CH_3.

Claim 6 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 4, wherein the phenyl group of R_2 is substituted with Cl or F in the *meta* position.

Claim 7 (currently amended): ~~A compound according to any one of claims 1-4,~~ The compound of claim 4, wherein the phenyl group of R_2 is substituted with Cl in *meta* and *para* position.

Claim 8 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 1, wherein R_4 is an aliphatic group, which includes oxygen atoms in one or more positions ~~is interrupted in one or more positions by oxygen atoms~~.

Claim 9 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 1, wherein R_4 is an aliphatic group, which ~~comprises~~ contains one or more carbonyl ~~group~~ groups.

Claim 10 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 1, wherein R_4 is an aliphatic group ~~that comprises~~ which includes a terminating functionality selected from the group ~~that consists~~ consisting of a carboxylic acid, nitrogen, oxygen, sulphur or any derivative thereof.

Claim 11 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 1, wherein R_1 is CH_3; R_2 is a phenyl group that has been substituted with Cl in *meta* and *para* position; and R_3 and R_4 are parts of a cyclic 5-membered group~~, which is optionally substituted~~.

Claim 12 (currently amended): ~~A compound according to~~ The compound of claim 11, wherein the cyclic 5-membered entity is substituted in a position directly adjacent to N with a C(O)-O-CH3 group.

Claim 13 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 1, which is capable of binding ~~human~~ to the constant region of a human IgG of κ-type, or a functional derivative thereof, with a binding constant of at least 10^{-3} M.

Claim 14 (currently amended): ~~A compound according to any one of the preceding claims,~~ The compound of claim 1, which is capable of binding to the constant region of a human IgG of κ-type, or a functional derivative thereof, via a binding pocket defined by the structure coordinates of the amino acids as shown in Fig 6.

Claim 15 (cancelled)

Claim 16 (currently amended): A sorption complex ~~comprised of a compound according to any one of claims 1-14~~ comprising the compound of claim 1 directly linked to the constant region of a Fab fragment of a human IgG of κ-type, or a functional derivative thereof.

Claim 17 (currently amended): A separation matrix for affinity chromatography, ~~which matrix comprises~~ comprising ligands coupled to a support, wherein the majority of the ligands are the compounds of claim 1 ~~as defined in any one of claims 1-14~~.

Claim 18 (currently amended): ~~A~~ The separation matrix ~~according to~~ of claim 17, wherein the ligands have been coupled to the support via linkers.

Claim 19 (currently amended): ~~A~~ The separation matrix ~~according to~~ of claim 17 ~~or 18~~, wherein the support is a porous polymeric particle.

Claim 20 (cancelled)

Claim 21 (currently amended): A system suitable for affinity chromatography, ~~which is comprised of a separation matrix as defined in any one of claims 17-19~~ comprising the separation matrix of claim 17 packed in a column.